Shanghai IASO Biotechnology Co., Ltd
Shanghai IASO Biotechnology Co., Ltd
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| IASO-782 in Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-08-10 | NCT07483346 | |
| IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 | 2026-06-01 | NCT07309900 | |
| IASO-782 in Autoimmune Hematological Diseases | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 | 2026-05-29 | NCT06534021 | |
| Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | cancer, neoplasm | Recruiting | Early phase 1 | 2022-04-27 | NCT05141253 | |
| An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | Solid Tumor | Recruiting | Early phase 1 | 2021-12-21 | NCT05166070 |